[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349830-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349830-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","transcriptional-profiling-of-the-tumor-microenvironment-of-recurrent-and-non-recurrent-stage-ii-colon-cancer","Transcriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer","","Predicting recurrence in stage II colon cancer remains clinically challenging. This study links tumor gene expression with clinicopathological features and recurrence by profiling primary tumors from 94 well-characterized patients. Expression profiling used the NanoString PanCancer IO 360™ panel covering 770 tumor progression and tumor microenvironment mRNAs, analyzed via hierarchical clustering, differential gene expression, and survival analyses. Results highlighted distinct pT4 immune- and myeloid-related patterns, 156 DEGs versus pT3, and independent prognostic markers SLC2A1 and VEGFA for time to recurrence and overall survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/transcriptional-profiling-of-the-tumor-microenvironment-of-recurrent-and-non-recurrent-stage-ii-colon-cancer/349830/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/transcriptional-profiling-of-the-tumor-microenvironment-of-recurrent-and-non-recurrent-stage-ii-colon-cancer/349830.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study in stage II colon cancer?","Question",{"text":63,"@type":64},"To uncover relationships between tumor gene expression, clinicopathological characteristics, and recurrence in patients with stage II colon cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was gene expression profiling performed?",{"text":68,"@type":64},"Primary tumors from 94 patients were profiled using the NanoString PanCancer IO 360™ panel, which measures 770 mRNAs related to tumor progression and the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"Which prognostic biomarkers were identified?",{"text":72,"@type":64},"SLC2A1 and VEGFA emerged as independent prognostic markers for time to recurrence and overall survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349830,1790257321,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTranscriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer  \nUlrik Korsgaard1,2,3,4, Maria Pihlmann Kristensen1,2,3, Sanne Kjær Frifeldt1,2,3, Jan Lindebjerg1,2,3, Torben Frøstrup Hansen2,3,5, Henrik Hager1,2,3,4 &  \nLasse Sommer Kristensen6􀀍  \nPredicting recurrences in patients with stage II colon cancer remains a clinical challenge. This study aimed to uncover connections between gene expression, clinicopathological characteristics, and recurrence in patients with stage II colon cancer. Gene expression profiling was conducted on primary tumors from 94 well-characterized patients with stage II colon cancer using the PanCancer IO 360™ panel from NanoString Technologies, which includes 770 mRNAs related to tumor progression and the tumor microenvironment. Unsupervised hierarchical clustering, differential gene expression (DEG) and survival analyses were used to describe the relationship between gene expression, clinicopathological characteristics, and recurrence. Unsupervised hierarchical clustering revealed distinct gene expression patterns in pT4 tumors, particularly in pathways involving immune cell localization and myeloid cell activity. DEG analysis identified 156 differentially expressed genes in pT4 versus pT3 tumors, includingthe important chemokines, CCL2 and CXCL8, and the cytokine LIF. In addition, 35 upregulated genes associated with migration and extracellular processes were identified in patients with recurrence.  \nFinally, SLC2A1 and VEGFA emerged as independent prognostic markers for time to recurrence and overall survival. In conclusion, this study unveiled distinct gene expression patterns in advanced pT4 tumors, and identified independent prognostic biomarkers that may prove useful in stage II colon cancer.  \nAbbreviations  \nCV Coefficient of variation  \nDEG Differential gene expression DFS Disease-free survival  \nEMT Epithelial mesenchymal transition FFPE Formalin fixed paraffin embedded GO Gene ontology  \nMDSC Myeloid-derived suppressor cell MMR Mismatch repair  \nNSCLC Non-small cell lung cancer  \nOS Overall survival  \nPCA Principal component analysis TILs Tumor-infiltrating lymphocytes  \nTME Tumor microenvironment  \nTTR Time to recurrence  \nUICC Union for International Cancer Control  \nQC Quality control  \n1Department of Clinical Pathology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.  \n2Danish Colorectal Cancer Center South, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark. 3Institute of Regional Health Research, University of Southern Denmark, Vejle, Denmark. 4Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. 5Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark. 6Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, Aarhus C, 8000 Aarhus, Denmark. 􀀍 email: [lasse@biomed.au.dk](lasse@biomed.au.dk)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nColon cancer is one of the most prevalent forms of cancer worldwide1. At the time of diagnosis, patients with stage II colon cancer have no visible lymph node metastases or distant metastases2. Stage II patients are primarily treated with surgical resection, while adjuvant chemotherapy is reserved for patients with certain high-risk criteria. However, these high-risk criteria remain controversial, as studies using the criteria show little to no benefit of treatment with adjuvant chemotherapy3,4 and some patients ultimately experience recurrence of the disease5. We have previously shown that quantification of coding and non-coding RNA transcripts using RNA sequencing is promising for the stratification of stage II colon cancer patients by recurrence risk, supporting the use of transcriptomic biomarkers in this setting6. However, there remains a need to extend these ","cbCaitZxGSqsfSbi","https://ap.wps.com/l/cbCaitZxGSqsfSbi","pdf",4819200,13,"English","# Introduction\n## Clinical problem and study rationale\n## Tumor microenvironment and immune interactions\n# Methods\n## Gene expression profiling with PanCancer IO 360™\n## Clustering, differential expression, and survival analyses\n# Results\n## Distinct pT4 expression patterns\n## Differentially expressed genes and recurrence-related signatures\n## Independent prognostic markers","[{\"question\":\"What was the main goal of this study in stage II colon cancer?\",\"answer\":\"To uncover relationships between tumor gene expression, clinicopathological characteristics, and recurrence in patients with stage II colon cancer.\"},{\"question\":\"How was gene expression profiling performed?\",\"answer\":\"Primary tumors from 94 patients were profiled using the NanoString PanCancer IO 360™ panel, which measures 770 mRNAs related to tumor progression and the tumor microenvironment.\"},{\"question\":\"Which prognostic biomarkers were identified?\",\"answer\":\"SLC2A1 and VEGFA emerged as independent prognostic markers for time to recurrence and overall survival.\"}]","Transcriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer | PDF",1790085842,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08d7a910c13f91fefc7bf6a9ffe5e83b.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7d2e9fde51f43b7ed55c2ef253cc982.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d876b5135eaac94547c86355bd891af.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca25b236967ed94e96e960638974feb9.webp",980,1287]